Treatment with Tezepelumab Reduces Serum Interleukin (IL)-5 and IL-13 in Patients with Severe, Uncontrolled Asthma to Levels Approaching those Observed in Healthy Individuals
2021
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI